Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
| Autor: | Catherine Weiss, Mette Krog Josiassen, Emmanuelle Weiller, Mika Juhani Hakala, John Ouyang, Mary Hobart, Stephen R. Marder, Peter Zhang |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Exacerbation Vital signs Thiophenes Quinolones Placebo 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Internal medicine Statistical significance medicine Humans Psychiatry Biological Psychiatry Brexpiprazole Positive and Negative Syndrome Scale business.industry Middle Aged medicine.disease 030227 psychiatry Psychiatry and Mental health Treatment Outcome chemistry Tolerability Schizophrenia Female business 030217 neurology & neurosurgery Antipsychotic Agents |
| Zdroj: | Acta Neuropsychiatrica. 29:278-290 |
| ISSN: | 1601-5215 0924-2708 |
| DOI: | 10.1017/neu.2016.57 |
| Popis: | ObjectiveReview efficacy, safety, and tolerability of brexpiprazole in patients with schizophrenia in short- and long-term phase 3 studies.MethodsPatients experiencing a current exacerbation of schizophrenia received brexpiprazole in two fixed-dose (2 and 4 mg), 6-week, placebo-controlled studies, one flexible-dose (2–4 mg), 6-week, placebo-control and active reference study, and one fixed-dose (1–4 mg), 52-week, placebo-controlled maintenance study.ResultsThe efficacy of brexpiprazole was demonstrated in the two short-term fixed-dose studies with statistically significant improvements from baseline in Positive and Negative Syndrome Scale (PANSS) total score compared with placebo. In the flexible-dose short-term study, treatment with brexpiprazole resulted in numerically greater improvements in PANSS total score than with placebo that approached statistical significance (p=0.056). A meta-analysis of these short-term studies showed a mean change in PANSS total score of −20.1, reflecting a clinically meaningful reduction in symptoms. In the maintenance study, brexpiprazole had a beneficial effect relative to placebo on time to exacerbation of psychotic symptoms/impending relapse (pConclusionsOverall, the results indicate brexpiprazole, used either short-term or as part of a long-term maintenance treatment programme, is an efficacious therapy option in adults with schizophrenia and has a favourable safety/tolerability profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|